Literature DB >> 17314271

Induction of tumorigenesis and metastasis by the murine orthologue of tumor protein D52.

Jennifer D Lewis1, Laura A Payton, Jill G Whitford, Jennifer A Byrne, David I Smith, Libang Yang, Robert K Bright.   

Abstract

Expression studies have consistently identified tumor protein D52 (TPD52) overexpression in tumor cells. Murine TPD52 (mD52) shares 86% identity with the human orthologue. To study a possible role for TPD52 in transformation, 3T3 fibroblasts were transfected with the full-length cDNA for mD52. Expression of mD52 was confirmed by reverse transcription-PCR (RT-PCR), real-time PCR, and Western blot analysis compared with 3T3 and vector-transfected 3T3 (3T3.V), and the resultant cell line was designated 3T3.mD52. At 4 weeks, 3T3.mD52 gained a 2-fold increase in growth rate, lost contact inhibition, and exhibited a marked phenotype change. Further characterization revealed an acquired ability for anchorage-independent cell growth. To determine whether 3T3.mD52 had become tumorigenic, naïve, healthy, immunocompetent syngeneic mice were inoculated subcutaneously with varying cell doses. Tumors measuring >1 cm(2) were detected 60 days postinoculation with 3T3.mD52, and a 50% subcutaneous tumor incidence was obtained with as few as 5 x 10(5) 3T3.mD52 cells. Remarkably, when lungs from 3T3.mD52 tumor-bearing mice were analyzed, numerous tumor nodules were observed, ranging from nodules less than 10 to nodules too numerous to count (inoculation with 1 x 10(5) and 5 x 10(6) cells, respectively). Further support for the metastatic capacity of 3T3.mD52 was the demonstration that transforming growth factor (TGF)-betaR1 (receptor) expression decreased and TGF-beta1 secretion increased in 3T3.mD52 compared with 3T3 controls. cDNA microarray analysis showed a gene expression pattern that further supported mD52-induced transformation and metastasis. Together, these data suggest that mD52 expression in 3T3 cells initiated cellular transformation, tumorigenesis, and progression to metastasis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17314271     DOI: 10.1158/1541-7786.MCR-06-0245

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  27 in total

1.  Radiation pharmacogenomics: a genome-wide association approach to identify radiation response biomarkers using human lymphoblastoid cell lines.

Authors:  Nifang Niu; Yuxin Qin; Brooke L Fridley; Junmei Hou; Krishna R Kalari; Minjia Zhu; Tse-Yu Wu; Gregory D Jenkins; Anthony Batzler; Liewei Wang
Journal:  Genome Res       Date:  2010-10-05       Impact factor: 9.043

2.  Lentivirus-mediated TPD52L2 depletion inhibits the proliferation of liver cancer cells in vitro.

Authors:  Ze-Ya Pan; Yun Yang; Hao Pan; Jin Zhang; Hui Liu; Yuan Yang; Gang Huang; Lei Yin; Jian Huang; Wei-Ping Zhou
Journal:  Int J Clin Exp Med       Date:  2015-02-15

3.  TPD52 expression increases neutral lipid storage within cultured cells.

Authors:  Alvin Kamili; Nuruliza Roslan; Sarah Frost; Laurence C Cantrill; Dongwei Wang; Austin Della-Franca; Robert K Bright; Guy E Groblewski; Beate K Straub; Andrew J Hoy; Yuyan Chen; Jennifer A Byrne
Journal:  J Cell Sci       Date:  2015-07-16       Impact factor: 5.285

4.  Adiponectin represses colon cancer cell proliferation via AdipoR1- and -R2-mediated AMPK activation.

Authors:  A Young Kim; Yun Sok Lee; Kang Ho Kim; Jae Ho Lee; Hee Kyu Lee; Su-Hwa Jang; Seong-Eun Kim; Gha Young Lee; Joo-Won Lee; Sung-Ae Jung; Hee Yong Chung; Sunjoo Jeong; Jae Bum Kim
Journal:  Mol Endocrinol       Date:  2010-05-05

5.  hABCF3, a TPD52L2 interacting partner, enhances the proliferation of human liver cancer cell lines in vitro.

Authors:  Juan Zhou; Ying Lin; Huili Shi; Keke Huo; Yanhong Li
Journal:  Mol Biol Rep       Date:  2013-09-20       Impact factor: 2.316

Review 6.  Tumor protein D52 (TPD52) and cancer-oncogene understudy or understudied oncogene?

Authors:  Jennifer A Byrne; Sarah Frost; Yuyan Chen; Robert K Bright
Journal:  Tumour Biol       Date:  2014-05-06

7.  Tumor protein D54 is a negative regulator of extracellular matrix-dependent migration and attachment in oral squamous cell carcinoma-derived cell lines.

Authors:  Yoshiki Mukudai; Seiji Kondo; Atsushi Fujita; Yasuto Yoshihama; Tatsuo Shirota; Satoru Shintani
Journal:  Cell Oncol (Dordr)       Date:  2013-03-26       Impact factor: 6.730

8.  Estrogen receptor β exerts tumor repressive functions in human malignant pleural mesothelioma via EGFR inactivation and affects response to gefitinib.

Authors:  Giulia Pinton; Warren Thomas; Paolo Bellini; Arcangela Gabriella Manente; Roberto E Favoni; Brian J Harvey; Luciano Mutti; Laura Moro
Journal:  PLoS One       Date:  2010-11-29       Impact factor: 3.240

9.  MAL2 and tumor protein D52 (TPD52) are frequently overexpressed in ovarian carcinoma, but differentially associated with histological subtype and patient outcome.

Authors:  Jennifer A Byrne; Sanaz Maleki; Jayne R Hardy; Brian S Gloss; Rajmohan Murali; James P Scurry; Susan Fanayan; Catherine Emmanuel; Neville F Hacker; Robert L Sutherland; Anna Defazio; Philippa M O'Brien
Journal:  BMC Cancer       Date:  2010-09-17       Impact factor: 4.430

10.  Overlapping synthetic peptides encoding TPD52 as breast cancer vaccine in mice: prolonged survival.

Authors:  Saied Mirshahidi; Victor G Kramer; James B Whitney; Sosthène Essono; Sandra Lee; Glenn Dranoff; Karen S Anderson; Ruth M Ruprecht
Journal:  Vaccine       Date:  2009-02-06       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.